van Es-Johansson An 4

What Happened
An van Es-Johansson, a director of Plus Therapeutics (PSTV), reported the exercise/conversion of a derivative on July 1, 2026 that resulted in the acquisition of 922 shares. The reported transaction shows an exercise/conversion price of $0.00 (no cash paid). A corresponding derivative disposition entry reflects the conversion of the RSU-derived right into common shares rather than an open‑market buy or sell.

Key Details

• Transaction date: July 1, 2026. Transaction code: M (exercise or conversion of derivative).
• Shares acquired: 922 common shares at $0.00 per share (total cash outlay reported $0).
• Disposition: a simultaneous conversion/termination of the derivative interest tied to those RSUs (reported as a disposition of the derivative instrument).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — each RSU equals a contingent right to one share; F2 — these RSUs vest in four substantially equal quarterly installments beginning July 1, 2026 (922 appears to be one quarterly installment, implying a full grant of 3,688 RSUs if all installments are equal).
• Timeliness: filing covers the period ending 2026-07-01 and was filed on 2026-07-01 (no late‑filing indication in the provided data).

Context
This was a routine vesting/conversion of restricted stock units into common shares (not an open‑market purchase or a sale). Such vesting is typically part of an equity compensation arrangement and does not by itself indicate the director is buying additional shares on the open market or expressing a new trading view.